Walter Stockinger
Private Equity Investor bij Hadean Ventures AS
Profiel
Walter Stockinger is currently the Managing Partner at Hadean Ventures.
AS since 2016.
Prior to this, he was a Board Member & Investor Director at Opsona Therapeutics Ltd.
Dr. Stockinger received his graduate and doctorate degrees from the University of Vienna.
Actieve functies van Walter Stockinger
Bedrijven | Functie | Begin |
---|---|---|
Hadean Ventures AS
Hadean Ventures AS Investment ManagersFinance Hadean Ventures AS (Hadean Ventures) is a venture capital firm that manages alternative investment funds. The firm was founded by Ingrid Helene Teigland Akay in 2014 and is headquartered in Oslo, Norway. | Private Equity Investor | 01-05-2016 |
Eerdere bekende functies van Walter Stockinger
Bedrijven | Functie | Einde |
---|---|---|
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Chief Investment Officer | - |
Opleiding van Walter Stockinger
University of Vienna | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Health Technology |
Hadean Ventures AS
Hadean Ventures AS Investment ManagersFinance Hadean Ventures AS (Hadean Ventures) is a venture capital firm that manages alternative investment funds. The firm was founded by Ingrid Helene Teigland Akay in 2014 and is headquartered in Oslo, Norway. | Finance |